<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632706</url>
  </required_header>
  <id_info>
    <org_study_id>mdc-TTG-CT-001</org_study_id>
    <nct_id>NCT04632706</nct_id>
  </id_info>
  <brief_title>Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedinCell S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAC Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MedinCell S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An early stage trial to check how safe and tolerable, as well as how the body handles&#xD;
      continuous daily use of Active IMP over 28 days in healthy volunteers to help with&#xD;
      coronavirus infection (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed information restricted because this is a Phase 1 clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study is a placebo-controlled, double-blinded exploratory study to investigate safety, PK and tolerability of a continuous use of the active drug (in 3 separate doses) in healthy subjects.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The study will be double-blinded. Patients will be randomised to receive 1 of 3 doses of the Active IMP or a matching placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Maximum Plasma Concentration [Cmax])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Time to Reach Cmax [Tmax])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Time to reach Cmax (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Trough Plasma Concentration [Ctrough])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>trough plasma concentration (Ctrough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>area under the plasma concentration-time curve from zero to 24 hours (AUC0-24h) concentration-time curve from zero to 24 hours (AUC0-24h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>area under the plasma concentration-time curve from zero to 48 hours (AUC0-48h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Average Plasma Concentration at steady state [Cavg ss])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>average plasma concentration at steady state (Cavg ss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations - (Apparent Terminal Half-Life [T1/2])</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>apparent terminal half-life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - Number of participants with treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Clinical safety data from adverse event (AE) reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - Number of participants with abnormal electrocardiograms (ECG)</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Assessment of cardiac electrical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - Number of participants with abnormal clinical neurological exam, as assessed by the investigator</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Assessment of neurological function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - Number of participants with abnormal urine and/or blood test, as compared to reference laboratory values</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Assessment of clinical laboratory results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - Number of participants with abnormal physical exams, as assessed by the investigator</measure>
    <time_frame>Study day 42 (at 14 days post the final dose)</time_frame>
    <description>Assessment of physical examination results</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>50mcg/kg (oral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 50mcg/kg from D2 to D28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75mcg/kg (oral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 75mcg/kg from D2 to D28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mcg/kg (oral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 100mcg/kg from D2 to D28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo (oral)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo using tablets identical to the Active IMP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Investigation of the safety, tolerability and the pharmacokinetic profile of the Active IMP in an exploratory study</description>
    <arm_group_label>100mcg/kg (oral)</arm_group_label>
    <arm_group_label>50mcg/kg (oral)</arm_group_label>
    <arm_group_label>75mcg/kg (oral)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo to the Active IMP.</description>
    <arm_group_label>Matching Placebo (oral)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Important Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male of any ethnic origin.&#xD;
&#xD;
          -  Subject is aged between 18 to 45 years, inclusive.&#xD;
&#xD;
          -  Subject has a body mass index (BMI) of 18.5 to 32.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Subject is â‰¥50 kg.&#xD;
&#xD;
          -  Negative reverse transcription polymerase chain reaction (RT-PCR) Test for severe&#xD;
             acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening and negative&#xD;
             lateral flow immunoassay test for SARS-CoV-2 at Day -1.&#xD;
&#xD;
          -  Healthy as determined by a responsible physician, based on medical evaluation&#xD;
             including medical history, physical examinations, neurological examinations,&#xD;
             concomitant medication, vital signs, 12-lead ECG and clinical laboratory evaluations.&#xD;
&#xD;
          -  Male subjects must use a condom during the study and for 3 months after their final&#xD;
             dose of study medication, if their partner is a woman of childbearing potential. In&#xD;
             addition, their female partner of childbearing potential must use an additional method&#xD;
             of highly effective contraception from first dosing until 3 months following final&#xD;
             dosing.&#xD;
&#xD;
        Important Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant history of abnormal physical or mental health (defined as any&#xD;
             subject requiring medical, psychological or pharmacotherapeutic intervention for&#xD;
             mental illness) interfering with the study as determined by medical history and&#xD;
             physical examinations obtained during Screening and Day -1 as judged by the&#xD;
             Investigator (including [but not limited to], neurological, psychiatric, endocrine,&#xD;
             cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder).&#xD;
&#xD;
          -  Any other concomitant disease or condition that could interfere with, or for which the&#xD;
             treatment might interfere with, the conduct of the study as outlined in this Protocol,&#xD;
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the&#xD;
             subject in this study.&#xD;
&#xD;
          -  Evidence of previous SARS-CoV-2 infection from medical history.&#xD;
&#xD;
          -  Ophthalmologic disorder (moderate and sever retina or optic nerve pathology; cataracts&#xD;
             excluded).&#xD;
&#xD;
          -  Subjects with a diagnosis of asthma or any other respiratory conditions.&#xD;
&#xD;
          -  A neurologic disorder that may compromise blood brain barrier permeability (stroke&#xD;
             within 90 days, brain tumour, multiple sclerosis, or other neuroinflammatory&#xD;
             condition, a neurodegenerative disorder, epilepsy) or history of seizures.&#xD;
&#xD;
          -  Positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibody&#xD;
             (anti-HCV) or human immunodeficiency virus I and II (anti-HIV I/II) at Screening.&#xD;
&#xD;
          -  The subject has participated in a clinical study and has received a medication or a&#xD;
             new chemical entity within 3 months or 5 half-lives (whichever is longer) prior to&#xD;
             first dosing of current study medication.&#xD;
&#xD;
          -  Use of any drugs that are known substrates of CYP3A4, P-glycoprotein (P-gp) from&#xD;
             within 4 weeks of Screening and unable to refrain from them until the end of the study&#xD;
             (e.g., rifampicin, quinidine, amiodarone, diltiazem, spironolactone, verapamil,&#xD;
             clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus,&#xD;
             indinavir, ritonavir or cobicistat). Use of critical CYP3A4 substrate drugs such as&#xD;
             warfarin or coumarin anticoagulants.&#xD;
&#xD;
          -  Recent or expected microfilaricidal drug use, including ivermectin, or travel history&#xD;
             to areas that are endemic for Loa loa or onchocerciasis (Angola, Cameroon, Central&#xD;
             African Republic, Chad, Democratic Republic of Congo, Ethiopia, Equatorial, Guinea,&#xD;
             Gabon, Republic of Congo, Nigeria and Sudan).&#xD;
&#xD;
          -  Use of medications having potential activity against SARS-CoV-2 such as&#xD;
             hydroxychloroquine, chloroquine, lopinavir, ritonavir, remdesivir, azithromycin, in&#xD;
             the 30 days prior to Screening and unable to refrain from them until the end of the&#xD;
             study.&#xD;
&#xD;
          -  Consumption of any food or drinks containing cranberry, pomegranate, starfruit,&#xD;
             grapefruit, pomelos, exotic citrus fruits or Seville oranges (including marmalade and&#xD;
             juices made from these fruits) within 14 days prior to first dosing until the end of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Richard</last_name>
    <role>Study Director</role>
    <affiliation>Chief Development Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Development Officer</last_name>
    <phone>+33 698 459099</phone>
    <email>joel.richard@medincell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence</name>
      <address>
        <city>Manchester</city>
        <state>Greater Mancherster</state>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Kelshaw</last_name>
      <phone>+44 (0) 161 275 9966</phone>
      <email>robbiekelshaw@macplc.com</email>
    </contact>
    <contact_backup>
      <last_name>L Cheung</last_name>
      <phone>+44 (0) 161 274 5400</phone>
      <email>louisacheung@macplc.com</email>
    </contact_backup>
    <investigator>
      <last_name>P M Leung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

